Aurora Kinase Inhibition Induces PUMA via NF-κB to Kill Colon Cancer Cells

Aurora kinases play a key role in mitosis and are frequently overexpressed in a variety of tumor cells. Inhibition of aurora kinases results in mitotic arrest and death of cancer cells, and has been explored as an anticancer strategy. However, how aurora inhibition kills cancer cells is poorly understood. In this study, we found that inhibition of aurora kinases by siRNA or small-molecule inhibitors led to induction of p53 upregulated modulator of apoptosis (PUMA), a BH3-only Bcl-2 family protein, in colorectal cancer cells irrespective of p53 status. Deficiency in PUMA increased polyploidy, improved cell survival, and abrogated mitochondria-mediated apoptosis induced by aurora kinase inhibitors. In response to aurora kinase inhibition, PUMA was directly activated by p65 through the canonical NF-κB pathway following AKT inhibition. Furthermore, PUMA was necessary for the chemosensitization and in vivo antitumor effects of aurora kinase inhibitors in colon cancer cells. These results suggest that PUMA induction mediates the apoptotic response to mitotic arrest imposed by aurora kinase inhibition, and may be a useful indicator for the anticancer activity of aurora kinase inhibitors. Mol Cancer Ther; 13(5); 1298–308. ©2014 AACR.

[1]  Jian Yu,et al.  Intestinal stem cell injury and protection during cancer therapy. , 2013, Translational cancer research.

[2]  Jian Yu,et al.  Crizotinib Induces PUMA-Dependent Apoptosis in Colon Cancer Cells , 2013, Molecular Cancer Therapeutics.

[3]  Jian Yu,et al.  The Multi-Targeted Kinase Inhibitor Sunitinib Induces Apoptosis in Colon Cancer Cells via PUMA , 2012, PloS one.

[4]  M. Malumbres,et al.  Killing cells by targeting mitosis , 2012, Cell Death and Differentiation.

[5]  A. Fojo,et al.  Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale , 2012, Clinical Cancer Research.

[6]  Jian Yu,et al.  Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth , 2011, Oncogene.

[7]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[8]  D. Mahadevan,et al.  Update on aurora kinase targeted therapeutics in oncology , 2011, Expert opinion on drug discovery.

[9]  Jason Clark,et al.  Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors , 2011, Cancer Chemotherapy and Pharmacology.

[10]  R. Medema,et al.  Shared and separate functions of polo-like kinases and aurora kinases in cancer , 2010, Nature Reviews Cancer.

[11]  Jian Yu,et al.  Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis , 2010, Proceedings of the National Academy of Sciences.

[12]  Jian Yu,et al.  PUMA Induction by FoxO3a Mediates the Anticancer Activities of the Broad-Range Kinase Inhibitor UCN-01 , 2010, Molecular Cancer Therapeutics.

[13]  H. Katayama,et al.  Aurora kinase inhibitors as anticancer molecules. , 2010, Biochimica et biophysica acta.

[14]  K. Glaser,et al.  Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization , 2010, Proceedings of the National Academy of Sciences.

[15]  J. Berlin,et al.  Aurora Kinase Inhibitors - Rising Stars in Cancer Therapeutics? , 2010, Molecular Cancer Therapeutics.

[16]  C. Belka,et al.  Aurora kinase inhibitor ZM447439 induces apoptosis via mitochondrial pathways. , 2010, Biochemical pharmacology.

[17]  Jian Yu,et al.  Growth factors protect intestinal stem cells from radiation-induced apoptosis by suppressing PUMA through the PI3K/AKT/p53 axis , 2009, Oncogene.

[18]  Stephen S. Taylor,et al.  How do anti-mitotic drugs kill cancer cells? , 2009, Journal of Cell Science.

[19]  Jian Yu,et al.  PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells , 2009, Oncogene.

[20]  Jian Yu,et al.  PUMA is directly activated by NF-κB and contributes to TNF-α-induced apoptosis , 2009, Cell Death and Differentiation.

[21]  Jian Yu,et al.  PUMA, a potent killer with or without p53 , 2008, Oncogene.

[22]  A. Dar,et al.  Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells. , 2008, Cancer research.

[23]  Jian Yu,et al.  Sp1 and p73 activate PUMA following serum starvation. , 2008, Carcinogenesis.

[24]  A. Musacchio,et al.  Molecular basis of drug resistance in aurora kinases. , 2008, Chemistry & biology.

[25]  Jian Yu,et al.  BH3 mimetics to improve cancer therapy; mechanisms and examples. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[26]  L. Zhang,et al.  SMAC/Diablo mediates the proapoptotic function of PUMA by regulating PUMA-induced mitochondrial events , 2007, Oncogene.

[27]  C Gélinas,et al.  Current insights into the regulation of programmed cell death by NF-κB , 2006, Oncogene.

[28]  T. Mak,et al.  FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal , 2006, The Journal of experimental medicine.

[29]  Peng Wang,et al.  PUMA Dissociates Bax and Bcl-XL to Induce Apoptosis in Colon Cancer Cells* , 2006, Journal of Biological Chemistry.

[30]  L. Zitvogel,et al.  Apoptosis regulation in tetraploid cancer cells , 2006, The EMBO journal.

[31]  Jian Yu,et al.  PUMA Sensitizes Lung Cancer Cells to Chemotherapeutic Agents and Irradiation , 2006, Clinical Cancer Research.

[32]  D. Green,et al.  Pharmacological manipulation of cell death: clinical applications in sight? , 2005, The Journal of clinical investigation.

[33]  J. Massagué,et al.  Cyclin-dependent Kinase Inhibitors Uncouple Cell Cycle Progression from Mitochondrial Apoptotic Functions in DNA-damaged Cancer Cells* , 2005, Journal of Biological Chemistry.

[34]  K. Kinzler,et al.  PUMA mediates the apoptotic response to p53 in colorectal cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[35]  T. Fojo,et al.  Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[36]  H. Katayama,et al.  Mitotic kinase expression and colorectal cancer progression. , 1999, Journal of the National Cancer Institute.

[37]  P. Cohen,et al.  Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B , 1995, Nature.

[38]  H. Withers,et al.  Comparison of the gastrointestinal syndrome after total-body or total-abdominal irradiation. , 1989, Radiation research.

[39]  M. Karin,et al.  Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. , 2009 .

[40]  Michael Karin,et al.  Is NF-κB a good target for cancer therapy? Hopes and pitfalls , 2009, Nature Reviews Drug Discovery.

[41]  C. Gélinas,et al.  Current insights into the regulation of programmed cell death by NF-kappaB. , 2006, Oncogene.